The big jobs numbers out this week came from this morning's U.S. Bureau of Labor Statistics' (BLS) Employment Situation report, which surprised to the upside in a major way: 353K new jobs created f...

Drugmakers Bristol-Myers Squibb Co (NYSE:BMY, ETR:RM, OTC:BMYMP) and Abbvie Inc (NYSE:ABBV) on Friday both reported better than expected financial results for the December quarter, sending shares o...

353K new jobs created for January are nearly double the 180K or so analysts were looking for.

The headline numbers for AbbVie (ABBV) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street est...

AbbVie NYSE: ABBV is turning an important corner in 2024 and is on track to resume growth. Its Humira-related patent cliff aside, the business is stronger than ever, and the patent cliff is more of...

Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), AbbVie (ABBV) and Novartis (NVS) are worth retai...

AbbVie (ABBV) came out with quarterly earnings of $2.79 per share, beating the Zacks Consensus Estimate of $2.76 per share. This compares to earnings of $3.60 per share a year ago.

AbbVie raises its fiscal 2027 sales expectations for Skyrizi and Rinvoq.

Pharmaceuticals company AbbVie (NYSE: ABBV) reported its Q4 and full year financial results for 2023 this afternoon. The American medical R&D powerhouse had some setbacks in the year, including dis...

AbbVie Inc. ABBV, +1.94% on Friday reported fourth-quarter sales that topped analysts' estimates, even as it faces low-cost competition for its top-selling drug, Humira.

There is a lot of good news to digest from the biotech sector. Not only does it offer lots of strong stocks in January, but it is also expected to grow rapidly.

Evaluate the expected performance of AbbVie (ABBV) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metri...

We see daily analyst upgrades and downgrades, coming with price targets. They can be helpful tools for investors, providing a more structured plan and helping to inject positivity surrounding futur...

Pharmaceutical companies are due to receive by Thursday the U.S. government's opening proposal for discounts it is seeking on 10 high-cost medicines, an important step in the Medicare health progra...

Medtronic's global medical device business has supported annual dividend raises since 1978, and it's well positioned for more growth. AbbVie's lead drug fell off a patent cliff last year, but soari...